Apr 1 |
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
|
Mar 20 |
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
|
Mar 19 |
Cyclacel Pharmaceuticals, Inc. (CYCC) Q4 2023 Earnings Call Transcript
|
Mar 19 |
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 13 |
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
|
Feb 20 |
Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference
|
Jan 30 |
Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer
|
Jan 2 |
Cyclacel Pharmaceuticals to Present at Biotech Showcase 2024
|
Dec 18 |
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data Suggesting Efficacy Against Tumors With CDKN2A, CDKN2B and MTAP Deletions
|
Nov 30 |
Cyclacel Regains Compliance With Nasdaq Listing Rule Following Filing of Its Form 10-Q With the SEC
|